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Abstract
The human immunodeficiency virus type 1 (HIV-1) is the primary cause of the acquired
immunodeficiency syndrome (AIDS), which is a slow, progressive and degenerative disease of the
human immune system. The pathogenesis of HIV-1 is complex and characterized by the interplay
of both viral and host factors. An intense global research effort into understanding the individual
steps of the viral replication cycle and the dynamics during an infection has inspired researchers in
the development of a wide spectrum of antiviral strategies. Practically every stage in the viral life
cycle and every viral gene product is a potential target. In addition, several strategies are targeting
host proteins that play an essential role in the viral life cycle. This review summarizes the main
genetic approaches taken in such antiviral strategies.
Introduction
HIV-1 is a lentivirus belonging to the retrovirus family.
The virus is diploid and contains two plus-stranded RNA
copies of its genome. The approximately 9 kb RNA
genome encodes at least 9 proteins, Gag, Pol, Env, Tat,
Rev, Nef, Vif, Vpu and Vpr of which only the former five
are essential for viral replication in vitro. HIV-1 primarily
infects CD4+  T-lymphocytes and monocytes/macro-
phages, but also astrocytes and cells of the central nervous
system (brain microglial cells) are targets. The infection
spreads to the lymphatic tissue that contains follicular
dendritic cells that may act as a storage place for latent
viruses. Over time, virus replication leads to a slow and
progressive destruction of the immune system. The devel-
opment of possible methods that can delay progression of
the infection or block replication of HIV-1 in infected
individuals has been the subject of dedicated research
efforts over the past decades. One important issue is that
HIV-1 makes use of the replication machinery of the host
cell, which minimizes the number of potential viral tar-
gets. On the other hand, the close host-virus relationship
limits the evolutionary freedom for the viral components
that interact with the host molecules.
The aim of this review is to take a comprehensive look at
the molecular, intracellularly based antiviral strategies
that have been reported in literature, and to discuss their
potential for development into clinical protocols. We will
not discuss vaccine-based strategies that recently have
been reviewed in [1] and [2].
Interfering strategies against HIV-1
The inhibition strategies can be divided into two groups:
The RNA-based strategies including anti-sense RNA (or
other chemically modified nucleic acids), RNA decoys
(sense RNA), ribozymes, RNA aptamers, small interfering
RNA (siRNA), microRNAs (miRNAs) and the protein-
based strategies including transdominant negative pro-
teins (TNPs), chimeric proteins (fusion proteins), nucle-
ases, anti-infective cellular proteins, intracellular single-
chain antibodies (sFvs) and monoclonal antibodies
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(Mabs). In addition, other strategies based on suicide
genes, protease inhibitors and nucleoside or non-nucleo-
side analogues have shown to possess the ability to reduce
HIV-1 replication.
The HIV-1 life cycle including the inhibiting strategies tar-
geted against the various steps in the viral life cycle is sum-
marized in Fig. 1 and listed in table 1. Below follows a
more detailed description of the strategies taken to target
individual steps of the viral life cycle. Note that strategies
targeting the viral genes or mRNA directly all possess an
uncertainty as to what viral function(s) are affected due to
the overlapping nature of some of the reading frames [3].
Virus-receptor interaction and entry
HIV-1 infection is initiated by binding of the virion gp120
surface subunit (SU protein) to the CD4 receptor. The SU
protein is attached to the virus by a non-covalent binding
to the gp41 transmembrane subunit (TM protein). Both
SU and TM are proteolytically cleaved from the Envelope
(Env) precursor protein by a cellular convertase, furin,
within the endoplasmatic reticulum (ER). Both remain
noncovalently attached and are targeted to the host
plasma membrane by vesicular transport. The SU protein
is responsible for receptor recognition on CD4+ T-lym-
phocytes and the TM protein mediates the fusion between
the viral membrane and the host cell membrane [4,5].
Binding to CD4 induces a structural alteration in SU that
exposes the binding site for a co-receptor of the chemok-
Summarization of the HIV-1 life cycle and the inhibiting strategies targeting the different steps in the viral life cycle Figure 1
Summarization of the HIV-1 life cycle and the inhibiting strategies targeting the different steps in the viral life cycle.
Step Inhibiting strategies
1. Virus-receptor interactions Ribozymes, anti-sense RNA, monoclonal antibodies, chemokine and their derivatives, 
peptides, small inhibiting molecules, soluble CD4, siRNA, intracellular anti-SU.
2. Virus entry Intracellular anti-SU, peptides, sFvs.
3. Reverse transcription Nucleosides and non-nucleosides analogues, anti-sense RNA, RNA decoys, 
ribozymes, siRNA, aptamers, sFvs, small peptides.
4. Proviral integration Oligonucleotides, dinucleotides, chemical agents, siRNA, nucleases, sFvs.
5. Transcription TNPs, RNA decoys, ribozymes, anti-sense RNA, sFvs, nucleases, siRNA, chemical 
agents.
6. Splicing and nuclear export RNA decoys, TNPs, anti-sense RNA, siRNA, sFvs, nucleases, ribozymes, aptamers, 
chimeric proteins, small inhibiting proteins, peptides.
7-9. Translation Anti-sense RNA, ribozymes, siRNA, shRNA/miRNA.
10. Assembly, release and maturation Anti-sense RNA, RNA decoys, TNPs, ribozymes, chimeric proteins, sFvs, anti-
infectious cellular proteins, nucleases, protease inhibitors, small peptides.Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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Table 1: 
Interfering 
strategy
Target RNA/protein Interference 
site(s)
Mechanism References
Anti-sense RNA Cellular CCR5 and CXCR4 co-
receptors
Viral entry Inhibition of CCR5 and CXCR4 gene expression 6, 18, 19
Psi-gag and U3-5'UTR-gag-env 
regions
Pre-integration Co-packaged with genomic RNA, inhibits RT in 
incoming virions
6
Cellular CyPA gene Pre-integration The skipping of internal CyPA encoding exons 
reduces CyPA biosynthesis and thereby inhibits the 
reverse transcription
37
Tat/TAR interaction HIV-1 transcription Inhibits transcriptional regulation of HIV-1 gene 
expression
6, 7, 45, 76
Rev/RRE interaction Nuclear export Inhibits transport of unspliced and single spiced viral 
RNAs
6
5'UTR HIV-1 translation Inhibits the translation process 6
Psi-gag region Viral assembly Inhibits packaging of genomic RNA 6, 7, 45
5'-leader-gag region Viral assembly Inhibits the formation of Gag and Env multimeric 
complexes during viral assembly.
7, 18
Env and Vif encoding regions Viral assembly Inhibits env and vif gene expression 70
Nef encoding region Viral release Inhibits nef gene expression and thereby CD4 and 
MHC I downregulation
7
Pol encoding region Viral maturation Inhibits pol gene expression 70
RNA decoys RT enzyme Pre-integration Competes with HIV-1 RNA for the binding of RT 6
HIV-1 TAR region Pre-integration Competes with cellular tRNA3
Lys for the binding to 
RT and primes the reverse transcription from the 
TAR region instead of the PBS region
6
Tat and Tat-containing RNA 
polymerase II transcription 
complexes
HIV-1 transcription Inhibits Tat regulated transcription 6, 7, 18, 51
Rev protein Nuclear export Recruits Rev molecules and thereby prevents their 
interaction with the viral transcript
6
NC domain of the Gag protein Viral assembly Inhibits packaging by interfering with the NC domains 
ability to recognize the genomic RNA
6, 45
Ribozymes Cellular CCR5 and CXCR4 co-
receptors
Viral entry Cleaves CCR5 and CXCR4 mRNAs 6, 18
HIV-1 Gag and Pol encoding 
region and the U5 region
Pre-integration Cleaves the viral RNA before reverse transcription is 
completed
6, 36
RRE and the Rev encoding region Nuclear export Cleaves the viral RNA 6, 7
U5 HIV-1 translation Cleaves off the 5'-cap structure localized on HIV-1 
mRNAs
6, 7
Psi Viral assembly Cleaves HIV-1 RNAs before packaging 6, 7
Gag encoding transcripts Viral assembly Inhibits the formation of multimeric Gag and Env 
complexes
7, 18
SU encoding region Viral assembly Cleaves different conserved regions in the SU 
sequence
7
Nef encoding region Viral release Inhibits downregulation of CD4 and MHC I 7
RNA aptamers RT enzyme Pre-integration Displays high affinity and specificity for the RT enzyme 
and acts as templates analogues
31
Rev protein Nuclear export Possesses higher affinity for Rev than the RRE 
sequence and can therefore interfere with Rev 
function
57
siRNA Cellular CCR5 and CXCR4 co-
receptors
Viral entry Impairs the SU-chemokine co-receptor interaction 21, 22
CD4 protein Viral entry CD4 protein expression inhibited 23, 24
CD4-binding domain of the SU 
protein
Viral entry Inhibits the CD4-SU interaction 26
The viral LTR region or the vif 
and nef encoding regions
Pre-integration Guides the viral genomic RNA towards a siRNA-
mediated destruction
34, 52
RT encoding region Pre-integration Inhibits RT gene expression 35
Cellular CyPA gene Pre-integration Reduces CyPA biosynthesis and thereby the reverse 
transcription
37
CA encoding region Pre-integration Mediates cleavage of pre-spliced viral RNA in the 
cytoplasm and prevents integration
23, 24, 42
Tat encoding region HIV-1 transcription Inhibits Tat transactivation 35, 49, 50Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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NF-κB p65 subunit HIV-1 transcription Inhibits NF-κB transcriptional activation 35, 49
3'-terminus of the nef gene HIV-1 transcription Mediates cleavage of all spliced and unspliced RNA 
produced from the provirus
42
Rev transcript Nuclear export Inhibits Rev mediated export of unspliced and single 
spliced RNAs
49, 61
Gag and Nef encoding regions HIV-1 translation Mediates cleavage of both spliced and unspliced RNA 
produced from the provirus
23, 24, 34, 
42
shRNA/ miRNA Nef encoding region HIV-1 translation nef shRNAs act by blocking RNA stability or RNA 
translation
62
Transdominant 
negative 
proteins (TNPs)
Interactions between Tat/TAR 
complex and cellular co-factors
HIV-1 transcription Tat-mutants inhibit the function of the Tat protein by 
recruiting important cellular co-factors
7, 18, 45
Rev protein Nuclear export Rev-mutants e.g. act by preventing the interaction 
with cellular co-factors or by sequestering the Rev 
protein in the cytoplasm
7, 18, 25, 57, 
58, 59
Cellular Sam68 Nuclear export Sam68 mutants inhibit Sam68 transactivation of RRE 
and Rev function
60
Cellular Tsg101 Viral assembly Tsg101 mutants inhibit the transport of the Gag 
polyprotein into multivesicular bodies
71
Vif protein Viral assembly Vif mutants block an early processing of the Gag 
protein
66
Cellular INI1 Viral assembly INI1 mutants e.g. interact with the integrase domain 
of the Gag-Pol polyprotein and interfere with prober 
multimerization of Gag and Gag-Pol
39
The formation of Gag and Env 
multimeric complexes
Viral assembly E.g. interferes with complex formation 4, 6, 18
Nef protein Viral release Nef mutants e.g. inhibit CD4 downregulation 66
SU protein Viral release Overexpressed CD4 variants bind and sequester 
virion progeny within the cell
19
HIV-1 protease Viral maturation Pro-mutants prevent protease activation 7
Chimeric / 
fusion proteins
SU protein Viral entry A tetrameric version of sCD4, PRO542, which is 
fused to the conserved region of IgG2, prevents the 
CD4-SU interaction
8, 13
Proviral DNA Pre-integration An IN targeted sFv-nuclease fusion protein associates 
with the pre-integration complex and cleaves proviral 
DNA after integration has occurred
7, 18
TAR element HIV-1 transcription Designed Tat-nuclease fusion proteins recognize and 
cleave all HIV-1 RNA transcripts
5
RRE sequence Nuclear export Designed Rev-nuclease fusion proteins recognize and 
cleave all HIV-1 RNAs carrying the RRE sequence
5
Rev protein Nuclear export A NS1RM-Rev mutant, with a dominant retention 
activity, forms mixed oligomers together with Rev and 
inhibits nuclear export
7, 57
The TAR and RRE elements HIV-1 transcription 
/ nuclear export
A designed fusion protein, Tev, containing the RNA 
binding domains of both Tat and Rev fused to a 
nuclease, inhibits both early and late viral gene 
products
5
Viral genomic RNAs Viral assembly Gag-, Vpr- and Nef-nuclease fusion proteins cleaves 
viral RNA, either during or after the viral assembly
5, 7
Psi-element Viral assembly A NC-nuclease fusion protein recognizes and cleaves 
all unspliced RNAs in the cytoplasm
5
HIV-1 protease Viral maturation An overexpressed Vpr fused to several protease 
cleavage sites overwhelms the protease activity by a 
competitive mechanism
7, 74
Nucleases Tat encoding region HIV-1 transcription Inhibits Tat transactivation 6, 7, 45
TAR element HIV-1 transcription Inhibits Tat transactivation 6, 7, 45
Chemokine 
ligands
Cellular CCR5 and CXCR4 co-
receptors
Viral entry E.g. interacts directly with the co-receptors, mediates 
receptor blockade or mediates receptor down-
regulation
8, 9, 11, 12, 
13, 14, 16
Anti-infectious 
cellular proteins
SU protein Viral entry A truncated form of CD4, sCD4, inhibits the fusion 
event by binding to the SU protein and thereby 
extending the distance to the TM protein
8, 13, 19
Intracellular 
antibodies (sFvs)
SU protein Viral entry Inhibits the CD4-SU interaction 18
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The TM pre-hairpin intermediate Viral entry Inhibits the interaction between the fusion peptide 
and the cell membrane
29
RT enzyme Pre-integration Inhibits RT function 7, 18
IN enzyme Pre-integration Inhibits IN function 7, 18
Tat protein HIV-1 transcription Interacts with the Tat protein and restrains it in the 
cytoplasm
7, 18
Rev protein Nuclear export Recruits Rev in the cytoplasm 7, 18, 25, 57
The CD4 binding region of the 
SU protein
Viral assembly Interacts with the Env protein and restrains it in the 
ER
7, 18
Monoclonal 
antibodies 
(Mabs)
Cellular CCR5 and CXCR4 co-
receptors
Viral entry E.g. inhibit the SU-chemokine co-receptor interaction, 
HIV-1 fusion or entry
12
Extracellular loop on CCR5 SU-chemokine co-
receptor interaction
Inhibits HIV-1 fusion and entry 12
Nucleoside 
analogues 
(NRTIs)
RT enzyme Pre-integration Prevents the continued polymerization of the DNA 
chain
8
Non-nucleoside 
analogues 
(NNRTIs)
RT enzyme Pre-integration Interact directly and non-competitively with the RT 
enzyme and inhibits its function
8
Integrase 
inhibitors 
(Oligonucleotid
es, dinucleotides 
and chemical 
agents)
IN enzyme Pre-integration These inhibiting agents either block the catalytic 
function of the IN enzyme by binding to the integrase 
binding site located in the viral DNA, or by interacting 
with the catalytic core domain of the IN enzyme itself
40, 41
Protease 
inhibitors
Protease enzyme Viral maturation Act as transition state analogous and bind to the 
protease more tightly than the natural substrate
11, 8, 73
Examples of 
other inhibiting 
agents
Cellular CCR5 and CXCR4 co-
receptor
Viral entry Chemokine ligands potently inhibit the SU-chemokine 
co-receptor interaction
8, 9, 10, 11, 
12, 13
Cellular CCR5 and CXCR4 co-
receptors
Viral entry Designed peptides e.g. act by disrupting helix-helix 
interactions, which may influence co-receptor 
structure, or by associating with the co-receptor 
surfaces and thereby inhibit the interaction with the 
SU protein
8, 12
Cellular CXCR4 co-receptor Viral entry AMD3100, a small organic molecule, acts by spanning 
the main ligand-binding cavity of CXCR4, which 
constrains the co-receptor in an inactive 
conformation
12
Cellular CCR5 co-receptor Viral entry Cyclophilin-18, a protein derived from T. Gondii acts 
as a CCR5 antagonist and thereby inhibits fusion and 
infectivity of R5 HIV-1 isolates
17
SU protein Viral entry CV-N, a 11 kDa protein with high affinity for the SU 
protein, inhibits the SU-CD4 interaction
15
The N- and C-peptide regions on 
the TM pre-hairpin intermediate
Viral entry Designed N-, C-, and D-peptides interacts with the 
pre-hairpin intermediate and inhibit the fusion event
13, 27, 28
RT enzyme Pre-integration Small peptides, about 15–19 amino acid long, act by 
interfering the dimerization process of the RT enzyme
30
The Tat/TAR interaction HIV-1 transcription The TR87 compound acts by competing with Tat for 
binding to TAR-RNA
46
Protein /TAR RNA interaction HIV-1 transcription Pyrrolo [2,1-c][1,4]benzodiazepine-oligopyrrolo 
hybrids act by interrupting binding of cellular proteins 
and Tat to the TAR-RNA
47
Protein /TAR RNA interaction HIV-1 transcription Aromatic polyamidines carrying a Br atom inhibit 
cellular and viral protein-TAR RNA interactions
48
Cellular NF-κB HIV-1 transcription NF-κB activity is inhibited by minocycline, a second-
generation tetracycline
38, 54
Rev Nuclear export Peptides targeted against the NES domain inhibit Rev 
function
57
The cellular protease furin Viral assembly Peptides mimicking a conserved target sequence 
inhibit furin activity and thereby cleavage of the Env 
protein within the ER
72
HIV-1 infected cells All A Tat-Casp3 fusion protein induces apoptosis after 
cleavage and activation by the HIV-1 protease
79
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ine family. The major co-receptors required for entry of
HIV-1 are the chemokine receptor molecules CCR-5 (R5
HIV-1 isolates) and CXCR-4 (X4 HIV-1 isolates), which
are used by monocytes/macrophage-tropic and T-cell
tropic HIV-1 viruses, respectively [6]. When the SU pro-
tein binds to the co-receptor the result is another struc-
tural alteration exposing the N-terminal part of TM. This
part, also known as the fusion-peptide, mediates the
fusion between the viral and host membranes. The Env
protein is also capable of mediating fusion between
infected and non-infected cells by a process known as syn-
cytium formation [4,7,8].
Current strategies are targeting particularly the CD4-SU
interaction, the SU-chemokine co-receptor interaction,
and the TM-mediated virus-cell membrane fusion process.
The SU-chemokine co-receptor interaction
CCR-5 and CXCR-4 co-receptors have specific chemokine
ligands/antagonists that possess the ability to block the
virus infection. The molecules that bind to the co-recep-
tors can be divided into four categories: naturally occur-
ring chemokines and their derivatives, peptides and small
molecules (< 1 kDa), and Mabs, which recognize epitopes
on for instance the extracellular domains of certain
receptors.
Examples of chemokine ligands (beta-chemokines) that
inhibit infection of R5 isolates include RANTES, a physio-
logical ligand for the HIV-1 co-receptors CCR3 and CCR5.
RANTES is actively secreted by normal T-cells. Derivatives
of this peptide have been used, including aminooxypen-
tane (AOP)-RANTES [9], and from a recent study, Nα-(n-
nonanoyl)-des-Ser1  [L-thioproline2, L-α-cyclohexyl-
glycine3] RANTES (PSC-RANTES) [10]. RANTES is an
antagonist that besides having the ability to interact with
CCR5 also has a downregulating effect on the co-receptor.
RANTES can however induce chemotaxis and promote
unwanted inflammatory side effects. Therefore AOP-
RANTES was created by chemical modification of the
amino terminus. This analogue does not promote any
inflammatory side effects, and in addition it can prevent
chemotaxis induced by e.g. RANTES. AOP-RANTES is a
very strong antagonist that has a high affinity for CCR5,
elicits rapid endocytosis of CCR5, and prevents recycling
of the co-receptor back to the surface. PSC-RANTES is
chemically identical to native RANTES except for the sub-
stitution of a nonanoyl group, thioproline, and cyclohex-
ylglycine for the first three N-terminal amino acids of the
native protein. This analogue acts in the same way, but has
shown more potent in vitro antiviral activity than AOP-
RANTES. Furthermore, it has successfully protected rhesus
macaques from intravaginal exposure to a chimeric sim-
ian/human immunodeficiency virus containing an R5-
tropic envelope of HIV-1 [10].
In addition to RANTES and its derivatives, the chemokine
ligands macrophage inflammatory proteins 1alpha/beta
(MIP-1alpha and MIP-1beta) also show an inhibiting
effect by mediating a receptor blockade [8,11-13]. Exam-
ples of chemokine ligands that inhibit infection of X4 iso-
lates include stromal cell-derived factor-1alpha (SDF-
1alpha) and its derivatives that inhibit HIV-1 fusion and
entry by minimizing the accessibility to the co-receptor on
the cell surface and by inhibiting the SU-CXCR4 interac-
tion [9,11-13].
The CCR5 amino-terminal domain is thought to play an
important role in virus fusion and entry. This knowledge
has been utilized in the development of anti-CCR5 Mabs
whose epitopes include residues in the amino-terminal
domain. Mabs of this kind strongly inhibit SU binding to
CCR5 but only moderately inhibit HIV-1 fusion and entry
[12]. Another type of Mab, the anti-ECL2 Mab whose
epitopes include residues from one of the extracellular
loops on CCR5 (ECL2), potently inhibits HIV-1 fusion
and entry, but only moderately inhibits SU binding [12].
PRO 140, also an anti-CCR5 Mab, inhibits viral fusion
with the cell membrane at concentrations that do not pre-
vent the CCR5 chemokine receptor activity. It binds a
complex epitope spanning multiple extracellular domains
on CCR5, and although it acts as a weak antagonist it does
not induce signaling or downregulation of CCR5. It is
thought that the antiviral effect is exerted through a mech-
anism involving receptor blockade [14]. Mab 12G5 is a
monoclonal antibody that recognizes an epitope on
CXCR4. This epitope is also present in ECL2, and binding
inhibits HIV-1 fusion [12,15]. A potential disadvantage of
this strategy is that binding of the antibody to a receptor
may trigger unwanted signal transduction [14,16].
Peptides, resembling the CCR5 transmembrane helices,
inhibit HIV-1 replication and chemokine signaling by dis-
rupting helix-helix interactions, which may influence the
CCR5 structure [12]. T22 is a positively charged cyclic 18-
mer antimicrobial peptide, which presumably inhibits
SU-CXCR4 interaction by associating with the negatively
charged surface of CXCR4 [8,12]. A truncated form of
SDF-1alpha, consisting of the 16 amino-terminal residues
of SDF-1alpha, also seems to possess such a blocking
effect [12].
Recently, a new kind of CCR5 antagonist has been discov-
ered in a protozoan parasite, Toxoplasma gondii [17]. This
protein, cyclophilin-18 (C-18), has several potential anti-
viral properties including CCR5 binding, induction of the
production of interleukin-12 (IL-12) from murine den-
dritic cells, inhibition of fusion and infectivity of R5 iso-
lates by co-receptor antagonism and blocking of syncytia
formation.Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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Small organic molecules, such as AMD3100, potently
inhibit HIV-1 replication by an interaction with residues
present on one of the CXCR4 extracellular loops, ECL2,
and residues within a transmembrane helix, TM4. Upon
binding to these residues AMD3100 spans the main lig-
and-binding cavity of CXCR4, which probably constrains
the co-receptor in an inactive conformation [12].
Individuals with a homozygous deletion in the gene
encoding CCR5 are healthy and protected against HIV-1
transmission, which suggests that down regulation may
not pose any clinical side effects. This knowledge has led
to the development of strategies that directly target the
mRNA encoding CCR5 or CXC4, either by ribozymes
[6,18], anti-sense RNA [6,18,19] or RNAi [20]. The latter
strategy, the siRNA approach, has led to successful block-
ing of HIV-1 entry, protection of cells from infection and
delay of virus replication [21-24]. Interestingly, it is
thought that single-stranded siRNAs (the anti-sense
strand of a siRNA duplex) act through the same RNAi
pathway, but at a later stage than double-stranded siRNA,
thereby requiring less time to exert their antiviral activity
[21,25].
The CD4-SU interaction
Soluble CD4 (sCD4) is an anti-HIV-1 protein, which can
be expressed and secreted from genetically engineered
cells. It is a truncated form of the CD4 receptor, composed
of the ectodomain that inhibits laboratory-adapted strains
of HIV-1. sCD4 probably prevents the binding of the virus
to the cell, by binding directly to Env, or indirectly by
inducing or repressing cellular factors that influence the
viral gene expression [18,19].
When sCD4 binds to SU it acts by extending the distance
to TM, which inhibits the fusion. But when used against
primary isolates, sCD4 was much less successful because
of a lower affinity for sCD4. Surprisingly, some isolates
became more infectious upon sCD4 treatment. An expla-
nation for this may be that an interaction between the SU
protein and sCD4 induces changes in SU, allowing it to
bind the co-receptor with higher affinity or increased
kinetics. In addition this interaction can eventually facili-
tate the fusion of HIV-1 with CD4- cells expressing the co-
receptor [13]. This has led to the development of a tetra-
meric version of sCD4, PRO542, in which the SU-binding
region of CD4 is fused to the conserved region of human
immunoglobulin IgG2. This fusion protein has a high
affinity for the SU protein and has shown promising
results in phase I clinical trials [8,13].
siRNA-directed silencing of CD4 mRNA expression has
been shown to specifically inhibit HIV-1 entry and thus
HIV-1 replication [23,24]. However, CD4 silencing in
vivo may interfere with its role in normal immune func-
tion. Thus an approach targeting the CD4-binding
domain of the SU protein would be more relevant. This
has successfully been achieved by expressing a 0.5 kb
dsRNA containing the major CD4-binding domain of the
SU protein, as the target of the env gene. By this approach
it has been possible to significantly suppress the expres-
sion of the HIV-1 CA-p24 antigen in human peripheral
blood mononuclear cells (PBMCs) and in HeLa-CD4+ for
a relatively long period of time [26].
Strategies based on the intracellular expression of anti-
bodies specific for the HIV-1 envelope (anti-SU) have also
been shown to inhibit virus replication. This strategy is
based on the usage of sFvs, containing the smallest struc-
tural domain that still possesses complete antigen and
binding-site specificity of the parental antibody. They are
secreted into the medium where they probably act as
inhibitors by direct interaction with the viral proteins [18]
to neutralize the virus [19].
Cyanovirin (CV-N), an 11 kDa protein originally isolated
from cyanobacteria, potently inactivates diverse strains of
HIV-1. It has a high affinity for the SU protein, and when
bound it inhibits the SU-CD4 interaction. CV-N possesses
the advantage that even high concentrations are non-toxic
and it is an extremely stable protein. CV-N has also been
coupled to a cytotoxin (Pseudomonas exotoxin), thereby
selectively killing HIV-1 infected SU-expressing cells [15].
The TM-mediated virus-cell membrane fusion
As the SU protein binds to CD4, it initiates conforma-
tional changes in SU, making the interaction between the
SU protein and the co-receptors more favorable. After
attachment to the co-receptor further conformational
changes occur in both the SU and TM proteins, thus weak-
ening their interaction. During this process a transitory
pre-hairpin intermediate of the TM protein is created, free-
ing the previously buried fusion peptide to interact with
the host-cell membrane. This exposes the N-peptide and
the C-peptide regions on the pre-hairpin intermediate
that have been targets for several inhibiting strategies
including synthetic C-peptides, N-peptides and sFvs.
C-peptides are based on the C terminal end of the fusion
peptide, and mimics this part of the fusion peptide when
it has its correct fusogenic conformation. T-20, a 36-
amino acid C-peptide, is a potent inhibitor of HIV-1 infec-
tion. It acts through a dominant negative mechanism and
interacts by binding to a conserved domain on the N-pep-
tide present in the pre-hairpin intermediate. The function
of this domain is to mediate a structural change, which
allows the pre-hairpin intermediate to form a fusogenic
hairpin state. Binding of T-20 inhibits this process and
thereby impedes fusion. Disadvantages of the C-peptide
strategy are the cost of C-peptide synthesis and theRetrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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relatively large amounts necessary for an antiviral effect.
In addition, their size makes them non-amenable to oral
routes of entry and they must be injected instead
[13,27,28].
The 5-Helix is a 25 amino acid N-peptide consisting of
five of the six helixes constituting the C-peptide. The pep-
tide is presumed to inhibit fusion, through binding with
high affinity to the C-peptide. However because N-pep-
tides have a strong tendency to aggregate the inhibition
could also be due to their intercalation into the TM
amino-terminal coiled coil [27,28].
A third kind of peptides named D-peptides have also
proven effective. These peptides are small 16–18 D-amino
acids residues that specifically bind to three hydrophobic
pockets present at the end of the N-peptide. Since such
peptides are unnatural, they are resistant to proteolytic
degradation, which makes them attractive for clinical use
[13,27].
Recently, a non-neutralizing antibody directed against
epitopes exposed on the fusion peptide has been reported
to possess antiviral effect [29]. This antibody does not
neutralize HIV-1 entry when produced as a soluble pro-
tein. However, when expressed on the cell surface as a
membrane-bound sFv, it is turned into a neutralizing anti-
body, which markedly inhibits HIV-1 replication and cell-
cell fusion by a mechanism that is thought to involve an
interaction with the exposed fusion peptide. This results
in inhibition of the subsequent fusion process. In the
same study, this sFv was targeted into the ER and trans-
Golgi network of HIV-1 susceptible cell lines where it was
found to significantly block the maturation process of the
viral Env protein resulting in an impairment of viral
assembly.
Reverse transcription and proviral integration
After fusion the viral core enters the cytoplasm and the
viral RNA is copied into double-stranded cDNA. This
process is mediated by the viral reverse transcriptase (RT)
enzyme in a complex consisting of RT, the viral genome,
and a cellular tRNA3
lys. The latter acts as primer and initi-
ates negative strand DNA synthesis by binding to the
primer binding site (PBS) region, located immediately 3'
to the U5 region [6,4]. RT possesses three essential
activities important for replication of the virus: RNA-
dependent DNA polymerase (i.e. reverse transcriptase),
RNase H activity (i.e. cleaves the genomic RNA in RNA/
DNA hybrids during DNA synthesis), DNA-dependent
DNA polymerase activity (i.e. for synthesis of the second
strand of the proviral DNA) [6,4].
Because RT is essential for viral replication it has been one
of the most popular targets. This has led to the following
antiviral strategies.
RT-targeted strategies
Inhibiting strategies against RT involve the utilization of
nucleosides and non-nucleosides. The nucleoside ana-
logues lack the 3'-hydroxyl group, prevent the continued
polymerization of the DNA chain, and are usually named
nucleoside reverse transcriptase inhibitors (NRTIs). Clini-
cally approved examples include Zidovudine (AZT),
Didanosine (ddI), Zalcitabine (ddC), Lamivudine (3TC),
Abacavir succinate and Stavudine (d4T) [8].
The non-nucleoside analogues, often referred to as non-
nucleoside reverse transcriptase inhibitors (NNRTIs), act
at the same step in the viral life cycle as the nucleoside
analogous, but by a significantly different mechanism.
Instead of acting as false nucleosides, the NNRTIs bind
directly and non-competitively to RT in a way that inhibits
the enzyme's activity. Examples of clinically approved
NNRTIs include Nevirapine, Delaviridine and Efavirenz
[8].
NRTIs bind to the deoxynucleoside triphosphate-binding
pocket, which is formed partly by the template-primer
nucleic acid and partly by the protein surfaces. NNRTIs
bind to a hydrophobic pocket exclusively present in the
RT enzyme of M subtype HIV-1. When used in combina-
tion they have a more pronounced antiviral effect.
The RNA decoy strategy aimed at RT involves the expres-
sion of RNAs lacking the PBS region, thus preventing it
from acting as template for reverse transcription. The RNA
competes with HIV-1 RNA when RT makes the first jump
during the first strand transfer [6]. Another decoy was
designed to be co-packaged together with genomic RNA
into new virions where it competes subsequently with
genomic RNA for RT binding [6]. Also, a designed
tRNA3
Lys mutant containing an 11 nucleotide 3'-end com-
plementary to the HIV-1 TAR region, shows an inhibiting
effect. This mutant competes with cellular tRNA3
Lys for the
binding to RT and primes reverse transcription from the
TAR region instead of the PBS region [6].
Other strategies against the RT enzyme involve the usage
of small peptides, about 15–19 amino acids long, that
inhibit RT activity by interfering with the dimerization
process of the RT enzyme. The amino acid sequence corre-
sponds to the so-called connection domain of RT, in par-
ticular a tryptophan-rich 19-mer sequence corresponding
to residues 389–407, which efficiently inhibits viral repli-
cation [30]. Likewise, strategies based on intracellular
expression of sFvs [7,18] and RNA aptamers [31-33] tar-
geted against the RT enzyme are potent inhibitors of HIV-Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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1 replication. The aptamers all recognize the same tem-
plate-primer-binding cleft on RT. Some of these RNA
aptamers have the potential to form pseudoknot-like sec-
ondary structures, which mimic the conformation of the
template-primer when associated with the RT enzyme.
Thus, these aptamers are termed template analogue RT
inhibitors (TRTIs). Selectivity of the RNA aptamers is
directly related to their three-dimensional structure. Utili-
zation of the TRTI aptamers has the following benefits: 1)
Aptamers have a unique specificity and a strong binding
affinity for the RT enzyme. 2) Aptamers inhibit the RT
enzyme competitively and will unlikely inhibit other viral
or cellular proteins, thus minimizing the risk for any
appreciable toxic side effects. 3) Since aptamers are
expressed in the infected cell, the aptamers will be co-
packaged into new virions and inhibit the next round of
replication. 4) Because of the large interface of the
aptamer-binding pocket, the risk of escape mutants is sig-
nificantly reduced. Furthermore, mutations in essential
binding domains, such as the template-primer-binding
pocket, will likely impair the binding of the RT enzyme to
the viral genome [31].
Anti-sense RNAs designed to be complementary to the
Psi-gag and the U3-5'UTR-gag-env regions have been
shown to inhibit RT in new virion particles. They are co-
packaged together with the genomic RNA into the virus
progeny, and inhibit reverse transcription by hybridizing
to the genomic RNA [6].
siRNAs directed against several regions of the HIV-1
genome, including the viral long terminal repeat (LTR)
and the accessory genes vif and nef have provided evi-
dence that the viral genomic RNA, as it exists within the
virion as a nucleoprotein reverse transcription complex, is
amenable to siRNA-mediated degradation [34]. In addi-
tion, siRNAs targeted against the RT gene alone have
shown potent inhibition of HIV-1 replication in MAGI
cells [35].
Hammerhead ribozymes targeted against the HIV-1 gag
region will cleave the viral RNA before reverse transcrip-
tion is completed [6]. Hairpin ribozymes, designed to
cleave a conserved site in the U5 region of the HIV-1 RNA
can likewise inhibit replication [6]. Especially the tRNAVal-
U5-ribozyme has shown promising results and is cur-
rently being tested in clinical trials. Moreover, hairpin and
hammerhead ribozymes targeted against the HIV-1 pol
region also show promising results [6,36]. In the latter
strategy a hammerhead ribozyme has successfully been
packaged into virions by linking it to the portion of the
HIV-1 genome that provides the packaging sequence [36].
This intravirion targeting ribozyme has in the same study
shown higher virus-suppressing activity than a nonpack-
ageable counterpart.
Since host tRNA3
Lys is being packaged into new virus par-
ticles, this molecule is often used when ribozymes have to
be co-packaged. An example is the tRNA3
Lys-hammerhead
ribozymes targeted against the PBS region. Besides cleav-
ing the HIV-1 RNA, the tRNA3
Lys-ribozyme inhibits
reverse transcription by competing with host tRNA3
Lys for
RT binding and/or for the binding to the PBS sequence.
Also, when bound to the PBS, the tRNA3
Lys-ribozyme is
unable to prime reverse transcription [6].
In a study closely related to the earlier mentioned CCR5
antagonist, C-18, human cyclophilin A (CyPA) has been
shown to be incorporated into HIV-1 during virion assem-
bly through interaction with an exposed proline-rich loop
within the capsid domain of Gag [37,38]. CyPA is
required for efficient viral replication but not for cell via-
bility meaning that its cellular function is probably being
compensated for by other factors. It has been proposed
that CyPA enhances HIV-1 infectivity during early post-
entry events, but may also be required for viral entry. The
proposed molecular interaction that underlies this
enhancement is the CyPA proteins ability to mask the
binding site for the human host restriction factor Ref1 and
thereby counteracting its inhibitory activity, allowing
reverse transcription to be completed. In an attempt to
reduce CyPA biosynthesis, two different anti-sense strate-
gies were used [37]. In one approach internal CyPA exons
are skipped by means of modified derivatives of U7 small
nuclear RNA (snRNA). U7 snRNA is the RNA component
of the U7 small nuclear ribonucleoprotein (snRNP)
involved in histone RNA 3'-end processing. By inserting
appropriate anti-sense sequences into U7 snRNA it has
successfully been converted from a mediator of histone
RNA processing to an effector of alternative splicing. The
other strategy involves the use of hairpin siRNA constructs
targeting two different parts of the CyPA coding region.
Both strategies greatly reduced the levels of CyPA, creating
CEM-SS T-cells that sustain HIV-1 replication.
The next step is the translocation of the cDNA containing
capsid into the nucleus. This process is mediated by inde-
pendent pathways involving either the Vpr accessory pro-
tein, the matrix protein (MA) or the integrase (IN)
protein. Vpr is thought to mediate the nuclear import of
the preintegration complex through the nuclear pore
complex (NPC) in non-dividing cells by interacting
directly with proteins in the NPC. This transfer of viral
DNA is mediated by a nuclear localization signal present
in the Vpr protein. Furthermore, it has been shown that
Vpr is involved in arresting HIV-infected cells in the G2
phase of the cell cycle, where the virus production has
been shown to reach a maximum level [4-7]. Integration
of proviral DNA is mediated by the viral IN enzyme by a
process that requires the host protein integrase interactor
1 (INI1 / hSNF5). IN consists of an N-terminal zinc fingerRetrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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domain, a catalytic core domain, and a C-terminal
domain that is important for binding HIV-1 LTR DNA
[39,40]. It has two enzymatic functions; DNA cleavage
and insertion of the provirus into the genome of the host
[4,7]. IN recognizes short inverted repeats (att sites) at
both ends of the proviral DNA and cleaves an AT
overhang at the 5' end. Then it catalyzes the non-specific
cleavage of the host genome and the subsequently liga-
tion of the 5' overhang to the cellular genome [4].
Several strategies aiming at the IN function have been
reported:
IN-targeted strategies
IN has no known functional analogue in human cells and
is therefore an appealing target for inhibiting strategies,
which generally involves the usage of oligonucleotides,
dinucleotides and different kinds of chemical agents, such
as dicaffeoylquinic acids (DCQAs) [40] and 2,4-dioxobu-
tanoic acid analogous [41]. The integrase binding site in
the U3 LTR region of the viral DNA contains a purine
motif, 5'-GGAAGGG-3'. This motif has selectively been
targeted by oligonucleotide-intercalator conjugates that
interact with the viral DNA through triplex formation,
thus blocking the catalytic functions of the IN enzyme
[41]. Disadvantages of these compounds include the low
intracellular permeability and the high mutation rate of
HIV-1 that may result in nucleotide substitutions in the
LTR.
The inhibiting effect of a dinucleotide, named pdCpI-
sodU, is due to its ability to interact with the catalytic core
domain [41]. This molecule consists of a natural D-deox-
ynucleoside and an isomeric L-related deoxynucleoside
joined together through a stereochemically unusual inter-
nucleotide phosphate bond, which makes the molecule
resistant to 5'- and 3'-exonucleases. Through binding the
molecule inhibits both the 3'-processing and the DNA
strand transfer step.
DCQAs are non-competitive inhibitors that act by irre-
versible binding to the catalytic core domain. The exact
chemical mechanism for this anti-IN activity is unknown,
but it is thought to be caused by a simple redox-process.
Two examples are 1-Methoxy-3,5-dicaffeoylquinic acid
and 3,4-Dicaffeoylquinic acid. Both are relative non-toxic
[40]. Finally, 2,4-dioxobutanoic acid analogous have
been reported to possess potent anti-IN activity through
inhibition of the DNA strand transfer step [41].
sFvs interacting with different domains on IN have been
isolated, and by fusion with a nuclease, a fusion protein is
created that can interact with IN in the pre-integration
complex, leading to cleavage of proviral DNA. Likewise
IN-specific sFvs have been shown to be inhibitory to HIV-
1 replication [7,18].
Finally, siRNAs targeted against the capsid protein, p24-
siRNA, is thought to interact with the gag gene in the
unspliced viral RNA when present in the cytoplasm.
Thereby, the viral RNA genome is cleaved before integra-
tion occurs [23,24,42].
HIV-1 transcription
Transcriptional regulation of HIV-1 gene expression is
controlled by co-operative and cell-specific interactions
between several host cells transcription factors, including
AP-1, NF-κB, NF-AT, NF-IL-6, CREB, IRF, Sp1, LEF-1/TCF-
1α, Ets-1 and USF, and the viral Tat protein [5,7,43]. The
Tat protein recognizes a stem-loop structure, the trans-
activation responsive element region (TAR), located in the
5'-end of the primary transcript (R region). Tat recruits a
cellular co-factor, positive transcription elongation factor
b (P-TEFb), composed of human cyclin T1 (hCycT1) and
CDK9 (a CTD kinase). The hCycT1 component binds to
the activation domain of Tat thereby increasing the affin-
ity for TAR. This results in the formation of a Tat/TAR
complex. Next, CDK9 phosphorylates the carboxy-termi-
nal domain of the host cell RNA polymerase II, which
stimulates the elongation process and thereby the overall
transcriptional efficiency [4,44].
The Tat/TAR interaction is essential for activation of HIV-
1 transcription and is therefore a popular target for inhib-
iting strategies. Another reason for choosing strategies
directed against this step is that the Tat-TAR interaction is
highly conserved. Thus the chance for development of
escape mutants is very low, due to the fact that mutations
in either Tat or TAR will cause an impaired interaction
between them and thereby abolish HIV-1 replication.
One strategy is to express a Tat protein that displays a
transdominant negative phenotype, which can inhibit the
replication of HIV-1. These proteins act as competitors for
Tat binding to an essential substrate or co-factor, or alter-
natively by associating with wild-type monomers to form
an inactive mixed multimer. Examples include Tat pro-
teins containing mutations in the activating domain, the
protein-binding domain, or in the TAR binding domain
[7,18,45]. An obvious disadvantage of this strategy is, as
mentioned earlier, the mutants' ability to recruit co-fac-
tors important for maintaining of a normal cellular func-
tion. Tat function can also be impaired by using a single-
chain antibody, sFv-Tat. When sFv-Tat interacts with the
Tat protein, it restrains Tat in the cytoplasm, thus hinder-
ing its transcription-regulating function in the nucleus
[7,18].Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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Several studies have shown promising results in blocking
the interaction of cellular TAR RNA-binding proteins and
viral Tat protein to TAR RNA. For instance these include a
study in which a compound termed TR87 directly com-
petes with Tat for binding to TAR [46], and a study involv-
ing pyrrolo [2,1-c][1,4] benzodiazepine-oligopyrrolo
hybrids, which appear to interrupt protein/TAR RNA
interactions and Tat-induced LTR-driven HIV-1 transcrip-
tion [47], and finally a study were two aromatic polyami-
dines carrying a halogen atom, termed TAPB-Br and TAPP-
Br, have demonstrated the potential to inhibit cellular and
viral protein-TAR RNA interactions [48].
An inhibiting effect has also been observed using anti-
sense-, nuclease-, or siRNA-based strategies directed
against tat mRNA [6,7,35,45,49]. Notably, a recent study
has demonstrated that tat siRNA delivered as pre-miRNA
precursor is 80 % more effective than tat siRNA expressed
as conventional short hairpin RNAs (shRNAs) [50].
Finally, anti-sense RNAs and nucleases targeting the TAR
element have also shown promise as antivirals [5-7,45].
A Tat-nuclease fusion protein has been engineered by fus-
ing the HIV-1 TAR RNA binding domain of HIV-1 Tat with
the RNase H domain of HIV-1 RT. Since TAR is present at
the 5' and 3' ends of all HIV RNAs, this Tat-nuclease can
recognize and cleave all HIV-1 RNA transcripts. The Tat
protein cycles in and out of the nucleus and the cleavage
of HIV-1 transcripts should therefore take place both in
the nucleus and in the cytoplasm [5].
TAR decoys represent another example of a suitable strat-
egy. These sense RNAs act by interacting with Tat-contain-
ing RNA polymerase II transcription complexes that
assemble on the HIV-1 promoter [7]. In addition the TAR
decoy RNAs solely recruit the Tat protein and the cellular
co-factor, P-TEFb, which is necessary for Tat-mediated
transactivation [18]. To make this strategy more effective,
the development of polymeric TAR decoys has been
accomplished. Constructs with up to 50 TAR elements
have been reported, but unfortunately these constructs
also recruit essential functional cellular co-factors [6,18].
A TAR decoy based on the element of HIV-2 (TAR-2) has
been shown to suppress HIV-1 replication more effective
that the decoy based on HIV-1. The explanation for this is
that the TAR-2 structure possesses three separate loop
regions and may therefore more effectively compete with
the single stem-loop structured TAR in HIV-1 for loop-
binding cellular factors [51].
Besides targeting the Tat encoding regions, siRNAs have
been directed against the Gag [23,24,42] and Nef [23,34]
encoding regions. Both siRNAs show antiviral effects. The
gag-targeted siRNA (p24-siRNA) is identical to the p24-
siRNA utilized when inhibiting the pre-integration step
and acts in the same manner. Since the nef gene is located
in the 3' end of the HIV-1 genome and in many of the viral
transcripts, a siRNA directed against the Nef encoding
region will reduce the number of viral transcripts. Also a
3'-LTR directed siRNA has shown potently to suppress
viral replication [42]. The 3'-LTR region was chosen, as it
is in the noncoding sequence before the poly(A) tail,
except for the Nef encoding RNA. Thus, by this specific
siRNA approach it is possible to target both spliced and
unspliced RNA produced from the provirus, whereas the
p24-siRNA approach only targets the unspliced viral RNA.
By combining these siRNAs a synergistic effect has been
observed [23,24,34,42]. The high specificity of the RNAi
approach also makes it vulnerable to inactivating muta-
tions in the viral genome as was observed in a recent study
[52]. Another promising strategy involving siRNAs
includes targeting of the NF-κB p65 subunit [35]. The NF-
κB p65 subunit is a key component for NF-κB transcrip-
tional activation of HIV-1. During the early phases of HIV-
1 infection in activated T lymphocytes, NF-κB binding to
the HIV-1 LTR serves to stimulate the generation of at least
some full-length transcripts for synthesis of Tat, which
then stimulates the transcriptional elongation process.
This is supported by the observation that siRNAs targeted
against the NF-κB p65 subunit show a decrease of HIV-1
replication in MAGI and Jurkat cells. However, the NF-κB
proteins are also critical for the regulation of immune
function. They regulate the expression of a variety of genes
encoding cytokines and cytokine receptors, chemokines,
cell adhesion molecules, and cell surface receptors that are
critical for T- and B-cell function. Therefore further studies
are required before p65-siRNAs can be used in clinical tri-
als [3,35,49]. Finally, a siRNA mediated knockdown of
cellular P-TEFb has surprisingly shown to decrease HIV-1
transcription and viral replication without being lethal to
the cell. It seems that there is a critical threshold of P-TEFb
kinase activity that is required for cell viability and Tat
transactivation. Moreover, it is suggested built-in intracel-
lular mechanisms allow cells to cope with changes in P-
TEFb protein levels [53].
Recently it has been reported that minocycline (MC), a
second-generation non-toxic tetracycline, possesses the
ability to inhibit NF-κB transcriptional activation and
thereby viral replication in microglia [54]. These resident
brain macrophages play a central role in AIDS dementia,
as they are the primary targets of productive infection in
the brain. Besides interrupting LTR activation, this agent
also seems to influence the production of cytokines,
chemokines, and other substances implicated in AIDS
dementia. It appears that MC may act by increasing NF-κB
complex formation, resulting in inactive homodimers.
This suggests that MC possess the ability to suppress both
viral production and inflammation.Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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HIV-1 mRNA splicing and nuclear export
Viral gene expression can be divided into an early and late
phase, which is Rev-independent and Rev-dependent,
respectively. In the early phase the newly transcribed
mRNA is spliced by the cellular splicing machinery into
multiply spliced transcripts, which mainly produces the
Tat, Rev and Nef proteins. When Rev has accumulated to
a critical level the mRNA production shifts from multiply
spliced to the singly spliced and unspliced transcripts,
characteristic of the late phase of gene expression. Rev
contains an RNA binding motif that directly interacts with
stem-loop IIB located within an RNA multi-stem-loop sec-
ondary structure, termed the rev response element (RRE),
which is present in the env gene of all incompletely
spliced viral mRNAs. The RRE can accommodate the bind-
ing of at least 8 Rev molecules, and at a certain threshold
concentration of Rev protein in the nucleus, functional
Rev/RRE complexes are formed, which greatly stimulate
the export of unspliced and singly spliced RNA to the cyto-
plasm where translation can proceed. Nuclear export is
mediated by cellular co-factors termed exportin 1 and
Ran-GTP, which interacts cooperatively with the Rev
nuclear export signal (NES) sequence [55]. The nuclear
import of Rev is mediated by the cellular co-factor impor-
tin-beta that interacts directly with a NLS sequence in Rev.
The host proteins B23 and p32 also interacts with the NLS
region and may be involved in nucleolar localization
[4,5,56-58]. The fundamental and essential function of
Rev has made it a popular target for therapeutic develop-
Schematic representation of the HIV-1 provirus and the different RNA species Figure 2
Schematic representation of the HIV-1 provirus and the different RNA species. Gag; group specific antigen, Gag-Pol; group spe-
cific antigen-polymerase, Env; envelope, Tat; trans-activator of transcription, Rev; regulator of expression of virion proteins, 
Nef; negative effector, Vif; virion infectivity factor, Vpr; viral protein r, Vpu; viral protein u, LTR; long terminal repeat.
HIV-1 RNA species
Full length unspliced RNA (gag/pol, genomic)
Incompletely spliced RNA (env/vif/vpr/vpu)
Completely spliced RNA (tat/nef/rev)
~9 kb
~4 kb
~2 kb
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ment [57]. Fig. 2 illustrates the structure of proviral DNA
and the different RNA species.
Many of the used strategies are based on inhibiting the
Rev/RRE interaction. Examples include Rev TNPs, RRE
RNA decoys, anti-sense Rev/RRE RNAs, siRNAs, sFvs,
nucleases, ribozymes, aptamers, chimeric proteins, and
small inhibiting molecules.
The most well characterized Rev TNP is the RevM10 pro-
tein, which contains amino acid substitutions within the
NES region. The ability of RevM10 to form multimeric
structures and to interact with RRE is not hindered by
these mutations, but the interaction with cellular co-fac-
tors is prevented leading to inhibition of Rev function
[7,18,25,57-59]. Making deletions in the NLS sequence
generates another kind of Rev TNP, the Rev38. The result
is a mutant that accumulates in the cytoplasm where it
sequesters the wildtype Rev protein by formation of inac-
tive oligomers, thereby hindering the transport of Rev into
the nucleus [18,57]. Likewise, Rev mutants lacking the
ability to form multimeric structures (RevSLT26 and
RevSLT40) are effective inhibitors. Of the mentioned
TNPs, RevM10 is the most potent inhibitor that has been
used in clinical trials [57].
RRE RNA decoys act by recruiting the Rev molecules and
thereby hindering their interaction with the viral tran-
script. Potent inhibition has been achieved by overexpres-
sion of a 45 nucleotide chimeric tRNA-RRE transcript [7].
This type of decoy unfortunately also binds essential cel-
lular co-factors, which has led to the design of minimal
RNA decoys that only contains the Rev binding site. An
example is a 41 nucleotide RRE SLIIAB RNA decoy that
has been used in clinical trials [6].
sFvs targeted against Rev potently recruit Rev proteins in
the cytoplasm, which accelerates the degradation of Rev
[7,18,25,57]. In a comparative study the effect of mono-
clonal sFv targeting either the NES region or the C-termi-
nal region of Rev was compared. The NES-specific sFv
demonstrated the best antiviral effect, even though the
binding affinity of the C-terminal sFv for Rev was signifi-
cantly higher [57].
Additional strategies for inhibition of Rev function
include, 1) RNA aptamers, possessing a higher affinity for
Rev than the RRE sequence, and which recognize other
epitopes than the natural RNA binding site on Rev [57], 2)
peptides that recognize the NES domain [57], 3) a
dominant negative mutant form of Sam68 (Src-associated
protein in mitosis), whose natural function is to interact
with RRE and thereby partially substitute or synergize
with Rev in RRE-mediated gene expression. In particular,
a C-terminally deleted mutant of Sam68 inhibits not only
Sam68 transactivation of RRE, but also Rev function [60].
Unlike RevM10, which competes with wildtype Rev for
binding to RRE in the nucleus, this Sam68 mutant is
mainly cytoplasmic, and binds RRE very poorly. However,
it retains the ability to bind Rev and the mechanism may
involve trapping of Rev in the cytoplasm by direct protein-
protein interaction. It is thought that the complex forma-
tion of Sam68 and Rev has a masking effect that inacti-
vates the Rev NLS domain. Since the Sam68 NLS domain
is deleted in the mutant it will not be able to substitute for
the missing Rev NLS domain, thus the HIV-1 replication
is inhibited. 4) chimeric proteins. One example is a con-
struct where the Rev protein is covalently attached to a
mutant form of the NS1 protein from the Influenza A
virus (NS1RM-Rev). It is thought that the fusion protein
and wildtype Rev form mixed oligomers, and due to the
nuclear retention activity of NS1, which is dominant over
the Rev-mediated nuclear export, it results in inhibition of
nuclear export of viral transcripts. NS1RM-Rev has an
antiviral effect equal to that of the RevM10 mutant [7,57].
As with inhibition of the Tat/TAR interaction, the anti-
sense and ribozyme strategies can also be targeted towards
the Rev/RRE interaction. Anti-sense directed against RRE
will inhibit Rev binding, whereas anti-sense directed
against the Rev encoding region will hinder the expression
of Rev protein [6]. The anti-sense RNAs can be either
unmodified or modified RNAs. E.g. a synthetic phospho-
rothioate oligodeoxynucleotide targeting Rev mRNA has
antiviral activity in chronically infected cells [25]. Unfor-
tunately, this type of anti-sense RNA strategy has shown
limited success as a therapeutic agent because of unsolved
problems such as efficacy, cell permeability, delivery and
cost. Ribozymes targeting RRE or the Rev encoding region
hinder viral replication by cleaving the targeted RNA [6,7].
By fusing the Rev protein with a nuclease it is possible to
create a nuclease with affinity for the RRE and which
therefore has the potential ability to specifically cleave all
HIV-1 RNAs carrying the RRE sequence [5]. Also, siRNAs
directed against the rev transcript potently inhibit virus
replication [49,61].
Finally, strategies based on small molecules that either
interact with host cellular proteins or bind to RRE, have
also been applied to inhibit Rev function. Due to the abil-
ity to interact with cellular proteins, these molecules are
often cytotoxic and therefore not usable for eventual clin-
ical trials. Nevertheless they are included here because less
toxic derivatives could be developed in the future. An
example is Leptomycin (LMB), an antibiotic agent that
interacts with the cellular protein CRM1, blocking the
binding to the Rev NES domain. A clear disadvantage of
LMB is, besides long-term toxicity, its ability to block the
transport of other proteins with a NES domain [25,56,57].Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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An overexpressed truncated version of the nucleopurine,
Nup214/CAN, delta-CAN, has shown a closely related
mechanism of inhibition. Delta-CAN retains the skill to
interact with CRM1 and inhibits Rev function in the same
way [56].
Aminoglycoside antibiotics, such as neomycin B and
derivatives have shown antiviral effect by binding to RRE
and thereby hindering the Rev/RRE interaction. The
binding of aminoglycoside antibiotics to RNA is very
unspecific, and together with a low selectivity, this drug is
unfortunately highly toxic for humans [25,57].
The intercalating dye, pyronin Y, completely blocks the
formation of the Rev/RRE complex in vitro. But since
pyronin Y also intercalates in DNA, the result is an ele-
vated level of cell death. Other intercalating agents, deriv-
atives of diphenylfuran, have been reported to inhibit the
Rev/RRE interaction by causing a conformational change
in RRE. These compounds possess the same disadvantages
as pyronin Y [25].
HIV-1 translation
As illustrated in fig. 2 translation of the non-spliced RNA
and single-spliced RNA result in the Gag and Gag-Pol pro-
teins, and in the Vpu, Vif, Vpr and Env proteins, respec-
tively. Translation of the completely spliced RNA results
in the Tat, Rev and Nef proteins [4,6-8].
Designed anti-sense RNAs directed against sequences
located in the 5' UTR of all HIV-1 mRNAs, would be able
to hinder the ribosome-complex in completing the trans-
lation process and thereby inhibit the protein synthesis
[6]. Hairpin ribozymes directed against the U5 region
have shown similar antiviral responses [6,7].
A study involving nef shRNAs corresponding to nef-
derived miRNAs, which recently have been demonstrated
to be produced in HIV-1-infected cells [62], shows the
potential to efficiently block RNA stability or mRNA trans-
lation. This may indicate that HIV-1 possess the ability to
regulate its own replication. Interestingly, another study
has shown that HIV-1 putatively encodes five candidate
pre-miRNAs, which potentially could target a large
number of cellular transcripts indicating that HIV-1 more-
over may have the potential to regulate the cellular milieu
[63].
Viral assembly, release and maturation
The virus particle is assembled at the plasma membrane.
In this process the Gag and Gag-Pol polyproteins interact
with each other by protein-protein interaction, most
probably via the capsid (CA) protein domain [64]. The
viral genome is packaged in a process in which the pack-
aging signal, Psi, is recognized by the nucleocapsid (NC)
protein domain of the Gag protein [65]. Another impor-
tant function of the NC domain is to mediate the forma-
tion of the RNA dimer via a palindromic sequence in the
dimer linkage structure (DLS) sequence, which is located
in the Psi sequence [4,6]. In addition several cellular
tRNAs are packaged. The assembly of the virus particle is
partly regulated by the Vpu and Vif proteins. The primary
function of the Vpu protein is to mediate the release of the
virus particle from the cell surface, by selectively targeting
the CD4 protein to a degradation pathway in the endo-
plasmic reticulum (ER). This permits the release of Env
protein from the ER, which may otherwise be complexed
with the CD4 protein, and further processing of the Env
protein can then proceed [4,5]. A current thought is that
Vif, besides influencing the late stages of virion assembly,
may also block premature processing of Gag precursor
protein by the HIV protease (Pro). This kind of temporal
control of Gag processing ensures the availability of the
CA, MA and NC peptides, when the assembly of the viral
components takes place at the plasma membrane
[4,66,67]. In addition, several studies have recently sug-
gested that Vif may possess another important function in
which it acts by overcoming the antiviral activity of a cel-
lular cytidine deaminase, APOBEC3G (CEM15) that
induces hypermutations in newly synthesized HIV-1 DNA
[68,69]. The mechanism by which Vif inhibits
APOBEC3G function is unclear, but it is thought to form
a complex with APOBEC3G, thus preventing its viral
encapsidation. Furthermore, Vif can target APOBEC3G for
degradation via the ubiquitin-proteasome pathway.
After virus budding from the cell surface, maturation of
the virus particle proceeds. At this stage in the virion life
cycle the Gag and Gag-Pol polyprotein are proteolytically
cleaved by the protease domain of Gag-Pol precursors.
Cleavage of Gag results in the MA, CA, NC and CEL viral
proteins. The MA proteins forms a matrix under the viral
envelope, the CA proteins condenses to form a conical
core surrounding the NC-coated RNA genome and the
CEL protein is thought to associate with the Env protein
and, in addition to mediating packaging of Vpr.
Cleavage of the Gag-Pol polyproteins, which is made by
ribosomal frameshifting during translation of unspliced
mRNA, results in the enzymatic proteins IN, RT and Pro.
Both the Gag and Gag-Pol precursors associate with the
Env protein by protein-protein interactions between the
MA domain and the TM protein. After maturation the
virus is ready for another round of infection [4]. Strategies
directed against this final step in the viral life cycle include
RNA decoys, TNPs, chimeric proteins, anti-infectious cel-
lular proteins, sFvs, nucleases, anti-sense RNAs,
ribozymes and peptides.Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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Viral assembly
The packaging signal Psi is a highly conserved RNA
sequence and is therefore an obvious target for inhibition
strategies. The Psi region contains four stem-loops located
near the 5' major splice donor and the start of the gag
open reading frame and is essential and sufficient for RNA
packaging [45].
RNA containing a 1.43 kb region anti-sense to the Psi-gag
region has been reported to inhibit packaging of genomic
RNA and thus HIV-1 replication with a higher efficiency
than the RevM10 mutant [6,7,45]. An antiviral effect has
also been observed by targeting anti-sense RNAs against
the Psi sequence, which act by hindering the NC domain
of the Gag protein in recognizing the packaging signal.
Likewise, ribozymes directed against the packaging signal
have also been shown to have a significant effect on viral
replication [7,6].
Since the Psi element is recognized by the NC domain,
one strategy is to design a NC-nuclease fusion protein,
which will recognize and cleave all unspliced HIV-1 RNAs.
The cleavage process occurs in the cytoplasm and this will
also inhibit the production of the Gag and Gag-Pol fusion
proteins [5]. Expression of the gag-gene has also been
reduced by using anti-sense RNAs complementary to the
5'-leader-gag region or by using ribozymes directed
against the gag transcripts [7,18].
The ability of the NC domains to recognize the genomic
RNA can be blocked with RNA decoys containing the Psi
sequence. These decoys may form dimers with HIV-1 RNA
and thereby compete with HIV-1 RNA dimers for packag-
ing into new virus particles [6,45].
The structural proteins, Gag and Env, form multimeric
complexes during viral assembly. By means of different
kinds of Gag TNPs it has been possible to inhibit this step.
Besides inhibiting viral assembly, these Gag TNPs also
interfere with the viral release process, the uncoating of
the viral genome and the reverse transcription [18]. A lim-
itation of using Gag TNPs is that the gag-gene contains an
inhibiting sequence, the CRS, which hinders the expres-
sion of the gag-gene if Rev is missing [4,6,18]. The poten-
tial effect of Env TNPs has also been tested, but this
strategy shows relatively low antiviral activity when com-
pared to Gag TNPs [18].
Given that one function of the Vif protein is to block early
processing of the Gag protein, it has inspired the develop-
ment of a Vif TNP that is missing the blocking function.
Applying this protein means that the virus assembly is
impaired, but a clear disadvantage is that HIV-1 has the
potential to evolve escape mutants [66]. Similar inhibi-
tion has been observed by directing anti-sense RNAs
against the Vif encoding region [70]. Another strategy
relies on the INI1 protein that is the only known host pro-
tein directly interacting with HIV-1 integrase. A minimal
integrase-binding fragment of INI1, S6, comprising
amino acids 183–294, potently inhibits HIV-1 assembly,
particle production and replication in a transdominant
manner. This inhibiting effect results from direct interac-
tion of the S6 protein with the integrase domain within
the Gag-Pol polyprotein. When the S6 protein binds to
integrase it is thought to interfere with proper multimeri-
zation of Gag and Gag-Pol by steric hindrance. In addition
it affects maturation, blocks an interaction of the cellular
assembly machinery with Gag-Pol and mediates the mis-
localization of viral proteins into different sub-cytoplas-
mic compartments of the cell. Besides being non-toxic,
another favorable feature of S6 is that it is unlikely to be
immunogenic, because it is a truncated form of a host pro-
tein. In addition, virions with mutations in the S6 binding
site will also be defective for interaction with INI1. This
minimizes the risk for the development of HIV-1 escape
mutants [39].
Recently, a specific inhibition of virus budding was dem-
onstrated by overexpression of an amino-terminal frag-
ment of tumour susceptibility gene 101 (Tsg101) [71].
The role of Tsg101 is to participate in the endocytic traf-
ficking pathway. It is presumed to bind to the Gag poly-
protein and subsequently mediate the transport into
multivesicular bodies (MVBs), which then carry their
cargo towards the cell surface.
By targeting an intracellular sFv specifically against the
CD4 binding region of the SU protein, it has been possi-
ble to make cells temporarily resistant to HIV-1 infection.
This sFv, named sFv105, acts by binding to the Env pro-
tein, and traps Env in the ER. This prevents the maturation
process in which Env is cleaved into the SU-TM proteins.
As a result, Env is prevented from reaching the cell surface
[7,18]. Another way to inhibit the maturation of Env is by
inhibiting the cellular protease furin [72]. Furin is a mem-
ber of the mammalian subtilisin-related proprotein con-
vertases that mediate cleavage of the Env protein at a
conserved Arg-Glu-Lys-Arg sequence. Peptides that mimic
this sequence have been reported to block furin activity.
Especially, a polyarginine peptide has shown promising
results without showing any toxic side effects on cultured
cells ex vivo or in mice in vivo.
Furthermore, anti-sense RNA approaches directed against
the Env message also belong to the applied strategies [70].
Multitarget ribozymes that target different sites in the SU
sequence also exert antiviral effects. Some of these
designed ribozymes bind and cleave up to nine different
conserved regions in the SU sequence [7].Retrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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A Gag-nuclease fusion protein can be packed into new vir-
ions and thereafter, in the proceeding rounds of infection,
efficiently cleave the viral genomic RNA. Since the Gag
protein has many essential functions it is unlikely that
HIV-1 will develop escape mutants when using the Gag-
nuclease. Vpr- and Nef-nuclease fusion proteins also seem
to cleave viral RNAs, either during or after viral assembly
[5,7].
Viral release
A Nef TNP has shown an antiviral effect by inhibiting
down-regulation of e.g. the CD4 cell surface protein. It is
thought that CD4 may interact with the Env protein
present on new viral particles, thus hampering viral
release from the cell surface [66]. Likewise, anti-sense
RNAs and ribozymes directed against a conserved 14
nucleotide region in the nef-gene also possess an antiviral
effect [7].
By overexpressing different kinds of CD4 variants in the
infected cell, it is possible to inhibit virus budding. The
reason is most likely that the CD4 variants possess the
ability to trap and restrain new virions in the cell [19].
Viral maturation
The HIV-1 protease plays an important role in virus mat-
uration. As mentioned earlier, the HIV-1 protease cleaves
the Gag and Gag-Pol polyproteins to form the structural
and enzymatic proteins. Consequently, the protease is a
potent target for inhibiting strategies. The current strate-
gies involve protease inhibitors that bind to the active site
of the HIV-1 protease and thereby inhibit processing of
the Gag and Gag-Pol polyprotein precursors. This results
in immature and noninfectious viral particles. The HIV-1
protease is an aspartyl protease and inhibitors have been
designed that optimally bind to the catalytic aspartate res-
idues and additionally to the water molecule that is criti-
cal for enzymatic action. The inhibitors are transition state
analogues that bind the enzyme much more tightly than
the natural substrate, making them competitive enzyme
inhibitors. Examples of approved protease inhibitors
include Saquinavir, Indinavir, Ritonavir, Nelfinavir and
Amprenavir [8,11,73].
Other strategies that target Pro involve the application of
Pro TNP [7], and the overexpression of chimeric Vpr pro-
tein in which the C-terminal region is fused to several
cleavage sites recognized by the protease. This will over-
whelm the protease activity by a competitive mechanism
and impair protease function [7,74]. Finally, anti-sense
RNAs targeting the Pol coding region inhibit this last step
in the viral life cycle [70].
Combination of antiviral strategies
By combining the different antiviral strategies, the effec-
tiveness can be increased and the chances of generating
escape mutants will be minimized. Examples of combina-
tion therapies include ribozymes combined with decoy or
anti-sense RNAs [6,75], and decoy RNAs combined with
anti-sense RNAs [6,76]. An autoregulated dual-function
anti-Tat gene is an example of the latter strategy, in which
both a polymeric TAR and an anti-sense Tat are combined
in one expression unit [76]. To accomplish gene expres-
sion in HIV-1 infected cells, a double-copy retroviral vec-
tor, in which gene expression is driven by the HIV-1 LTR,
is used. By this approach anti-Tat gene expression is upreg-
ulated only in HIV-1 infected cells.
The RT and Pro inhibitors are preferentially not used
alone to avoid the risk of generating viral escape mutants.
By combining the different kinds of inhibitors (usually a
combination of two nucleoside analogues with either a
protease inhibitor or a non-nucleoside analogue) signifi-
cant inhibition of HIV-1 is achieved. This combination
strategy is also known as HAART (highly active antiretro-
viral therapy). Because nucleoside and non-nucleoside
analogues act on two different positions on the RT
enzyme they will not compete for binding and when used
in combination they exhibit a more potent effect. The dis-
advantage concerning this strategy is the relative strong
toxic effects related to these RT drugs. Another problem
arises if the prescribed treatment is not exactly followed
and resistant viral mutants emerge [31].
When combining strategies involving ribozymes and RNA
decoys one can obtain better results than by using one of
the strategies. This is clearly illustrated by the tRNAVal-
RRE-SLII-U5 hairpin ribozyme, in which SLII (stem loop
II) contains the Rev protein-binding site that acts as a
decoy [6].
In an attempt to interfere with two essential HIV-1 activi-
ties at the same time, a double transdominant negative
Tat-Rev fusion protein, Trev, has been designed. This
fusion protein inhibits both Tat transactivation and Rev
mediated nuclear transport [18]. A similar designed
fusion protein, Tev, contains the RNA binding domains of
both Tat and Rev, and can thus target both TAR and RRE
within the HIV-1 RNA. Furthermore, a nuclease was fused
to the Tev protein. The result is an inhibition of both early
and late viral gene products. Tev contains a NLS and is
therefore predicted to act primarily within the nucleus [5].
The combination of an anti-Rev sFv, which targets the Rev
activation domain, and a ribozyme that targets RRE, or an
RRE RNA decoy, which recruits the Rev molecules, has
also shown good results [7]. Promising results have also
been described by using a vector expressing threeRetrovirology 2005, 2:10 http://www.retrovirology.com/content/2/1/10
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products, the U5 ribozyme, a ribozyme targeted against
the Env/Rev encoding regions, and a RRE decoy respec-
tively [18].
Strategies based upon suicide genes
Conditional expression of suicide genes in cells infected
with HIV-1, e.g. by expression from a Tat dependent pro-
moter or under Rev dependent control, has been designed
in different versions. Examples of suicide gene approaches
include engineering cells with a diphtheria toxin A-chain
(DT-A) gene, a cytosine deaminase gene, a herpes simplex
virus (HSV) thymidine kinase (tk) gene, and a herpes sim-
plex shutoff (vhs) gene.
DT-A is a very effective cellular toxin that kills cells by
blocking the protein synthesis via the ADP-ribosylating
elongation factor 2 [77]. Cytosine deaminase mediates
cell death through the conversion of 5-fluorocytosine to
the potent cytotoxic agent 5-fluorouracil [18], and the
HSV thymidine kinase mediates cell death by metaboliz-
ing nucleoside analogues, such as Ganciclovir and Acyclo-
vir, into toxic analogues [7,18]. The latter strategy has
been further explored in a study involving a live-attenu-
ated form of HIV-1 in which the nef gene has been deleted
and instead engineered to express the thymidine kinase
gene [78]. This marked live-attenuated virus vector may be
useful to accrue baseline information on the immunolog-
ical benefits of a replicating vaccine. The safety profile of
such a vaccine vector is supported by the possibility to
remove cells harboring integrated proviral genomes if
necessary.
Another approach involves the design of a hybrid mole-
cule consisting of the human CD4 and a modified version
of the Pseudomonas exotoxin A (CD4-PE40). This mole-
cule binds to infected cells by a CD4-SU interaction at the
cell surface and, after uptake, the exotoxin inhibits protein
synthesis, thus leading to cell death [7].
Finally, the last example involves a modified apoptosis-
promoting caspase-3 protein, Tat-Casp3, which acts by
cleavage of the inhibitor of caspase-activated DNase,
resulting in the activation of caspase-activated DNase and,
ultimately, cell death. In this design the endogenous
cleavage sites have been substituted with the HIV proteo-
lytic cleavage sites, and the Pro domain of the modified
Casp3 protein was removed and substituted with the Tat
transduction domain. Hence, the fusion protein is only
activated by the HIV protease in infected cells, resulting in
apoptosis, whereas in uninfected cells it remains in the
inactive zymogen form. Tat-Casp3 proteins may also be
packaged inside the virion and kill the virion after it buds
from the cell and/or initiate apoptosis immediately after
subsequent infection of a cell [79].
Conclusion
In spite of the astonishing diversity of methods developed
as antivirals against HIV-1, still many problems remain.
Perhaps the most difficult problem to solve is the remark-
able ability of HIV-1 to evade the different inhibiting strat-
egies. The selection pressure enforced by the treatment
may result in the selection of escape mutants that are
more pathogenic than the original virus. For instance:
Blocking the interaction with CCR5, which is the prima-
rily used co-receptor, could result in usage of both the
CCR5 and the CXCR4 co-receptors or CXCR4 alone. The
outcome will be an accelerated reduction of CD4+ T-cells
and thereby a progression of the disease [80]. The risk of
evolution of a virus variant that uses new co-receptors is
not unthinkable. To obtain long-term inhibition and to
avoid escape mutants, it is necessary to combine the dif-
ferent strategies, so that several steps in the viral life cycle
are inhibited at the same time.
RNAi is a very promising novel approach that in principle
will provide a large number of new targets that may be
combined, but unfortunately one of the biggest hurdles is
the in vivo delivery problem, which needs to be
addressed. A gene therapy approach may be used to make
hematopoietic stem cells resistant to HIV-1, which could
eventually lead to (partial) restoration of the immune
system.
In spite of the advanced technology used in the different
virus intervention strategies and the rapidly growing
knowledge about the molecular biology of HIV-1, it has
not yet been accomplished to block HIV-1 replication
completely. Hopefully, scientists will succeed to push the
balance of the virus-host battle in the right direction so
that the immune system will be able to handle the
remaining viruses, or vaccine strategies may be added to
clear the virus. Independently of the path taken, it will
most likely require that the latent reservoirs of virus are
activated to make them more vulnerable to treatment. A
combination of these directions may eventually lead to a
complete eradication of the virus in infected patients.
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